

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2003

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	4Q `03 vs. 4Q `02					
	TOTAL % CHG	TOTAL \$ MM	U.S. % CHG	U.S. \$ MM	Foreign % CHG	Foreign \$ MM
AGGRASTAT	-40%	\$ 22	-94%	\$ 1	12%	21
ARCOXIA	*	23	-	-	*	23
CANCIDAS	*	90	*	55	*	35
COZAAR / HYZAAR	1%	690	-20%	237	17%	453
CRIXIVAN / STOCRIN	-20%	62	-54%	14	1%	48
EMEND	*	8	*	8	*	0
FOSAMAX	-6%	650	-30%	324	42%	326
INVANZ	59%	12	28%	8	*	4
MAXALT	7%	94	-1%	65	31%	29
PRIMAXIN	-15%	149	-61%	26	15%	123
PRINIVIL / PRINZIDE	*	16	*	4	-28%	12
PROPECIA	7%	64	0%	27	13%	37
PROSCAR	2%	168	-10%	76	16%	92
SINGULAIR	0%	507	-15%	328	47%	180
TIMOPTIC / TIMOPTIC XE	0%	43	-24%	4	3%	39
TRUSOPT / COSOPT	16%	137	7%	56	23%	80
VASOTEC / VASERETIC	-2%	209	47%	(1)	-2%	211
VIOXX	95%	731	*	436	28%	295
ZOCOR	-30%	1,214	-29%	762	-31%	452
HEPATITIS VACCINES	-5%	53	-6%	44	-4%	9
VIRAL VACCINES	-3%	122	-7%	111	69%	12
OTHER VACCINES	13%	92	12%	78	18%	14

* > 100%

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	4Q `03	% CHG.	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	<u>\$ 5,627</u>	<u>-7%</u>	<u>-13</u>	<u>1</u>	<u>5</u>
U.S. (\$ MM)	3,151	-14%	-16	2	0
Foreign (\$ MM)	2,476	3%	-8	-1	12

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FULL YEAR
2003

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	DECEMBER YTD `03 vs. DECEMBER YTD `02					
	TOTAL % CHG	TOTAL \$ MM	U.S. % CHG	U.S. \$ MM	Foreign % CHG	Foreign \$ MM
AGGRASTAT	-16%	\$ 96	-67%	\$ 18	27%	78
ARCOXIA	*	70	-	-	*	70
CANCIDAS	*	276	*	166	*	110
COZAAR / HYZAAR	14%	2,486	-2%	899	26%	1,587
CRIXIVAN / STOCRIN	-1%	291	-14%	92	6%	199
EMEND	*	27	*	26	*	1
FOSAMAX	19%	2,677	2%	1,563	56%	1,114
INVANZ	*	37	*	28	*	9
MAXALT	13%	324	5%	224	34%	100
PRIMAXIN	7%	629	-3%	179	12%	450
PRINIVIL / PRINZIDE	-75%	116	-85%	61	-19%	55
PROPECIA	12%	239	13%	111	12%	128
PROSCAR	11%	606	2%	272	19%	334
SINGULAIR	35%	2,009	30%	1,399	48%	611
TIMOPTIC / TIMOPTIC XE	-4%	160	-34%	16	1%	144
TRUSOPT / COSOPT	14%	484	8%	202	19%	283
VASOTEC / VASERETIC	-4%	764	*	(12)	-2%	775
VIOXX	2%	2,549	-9%	1,535	24%	1,014
ZOCOR	-8%	5,011	-1%	3,144	-17%	1,868
HEPATITIS VACCINES	6%	241	6%	204	8%	38
VIRAL VACCINES	-4%	534	-7%	494	90%	40
OTHER VACCINES	14%	281	11%	229	28%	52

* > 100%

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	YTD `03	% CHG.	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	<u>\$ 22,486</u>	<u>5%</u>	<u>0</u>	<u>1</u>	<u>4</u>
U.S. (\$ MM)	13,321	1%	-1	2	0
Foreign (\$ MM)	9,165	11%	1	-1	11

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2003

OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (millions of dollars)

	4Q `03	4Q `02	YTD 2003	YTD 2002
INTEREST INCOME	\$ (72.2)	\$ (107.3)	\$ (308.7)	\$ (415.1)
INTEREST EXPENSE	80.0	98.1	350.9	390.8
EXCHANGE (GAINS)/LOSSES	(3.3)	(18.7)	(28.4)	(7.8)
MINORITY INTERESTS	37.2	44.5	168.7	214.2
AMORTIZATION OF INTANGIBLES	36.5	30.1	140.8	120.0
Other, net	(134.7)	23.6	(404.9)	(99.5)
TOTAL	\$ (56.5)	\$ 70.3	\$ (81.6)	\$ 202.6

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	4Q `03	4Q `02	YTD 2003	YTD 2002
IVOMEK, HEARTGARD, other avermectins	\$ 123	\$ 112	\$ 475	\$ 462
FRONTLINE	91	77	576	486
Biologicals	117	102	422	376
Other Animal Health	59	47	211	181
Poultry Genetics	41	40	154	157
TOTAL MERIAL SALES	\$ 431	\$ 378	\$ 1,838	\$ 1,662

Aventis Pasteur-MSD	4Q `03	4Q `02	YTD 2003	YTD 2002
HEPATITIS VACCINES	\$ 18	\$ 20	\$ 74	\$ 69
VIRAL VACCINES	11	8	51	35
Other Vaccines	140	116	543	442
TOTAL AP-MSD SALES	\$ 170	\$ 144	\$ 669	\$ 546

Merck / Schering-Plough Collaboration	4Q `03	4Q `02	YTD 2003	YTD 2002
Zetia (Worldwide)	\$ 164	\$ 25	\$ 469	\$ 25
TOTAL	\$ 164	\$ 25	\$ 469	\$ 25